Insulin Degludec (Tresiba): Dosing, Comparisons, and Clinical Evidence

What Is Insulin Degludec and How Does It Work?

Insulin degludec is a modified basal insulin that forms soluble multi-hexamers at the injection site, then releases monomers slowly into the bloodstream. This biochemical property produces an action profile that is flatter and more predictable than older long-acting insulins. The clinical result is stable overnight glucose coverage with a lower peak-to-trough variation than glargine U-100.

After subcutaneous injection, insulin degludec binds albumin and fatty acids in the circulation, which extends its effective half-life to more than 25 hours in most adults. Steady state is reached after two to three days of once-daily dosing. Because the action curve is so flat, a missed or late dose causes less glucose excursion than with shorter-acting basal insulins. The FDA prescribing information confirms that injections may be given at any time of day, provided at least 8 hours separate consecutive doses. [1]

Insulin degludec works the same way endogenous insulin does at the receptor level: it binds the insulin receptor, suppresses hepatic glucose output, and promotes glucose uptake in muscle and fat tissue. Unlike rapid-acting or short-acting insulins, it does not cover meal-time glucose spikes. Patients with type 1 diabetes always need a concurrent rapid-acting insulin (such as lispro or aspart) alongside Tresiba.

FDA-Approved Indications and Patient Selection

The FDA approved insulin degludec in September 2015 for glycemic control in adults with type 1 and type 2 diabetes. A 2019 label update extended approval to pediatric patients aged 1 year and older. [2]

Type 1 diabetes requires insulin from the point of diagnosis. Tresiba serves as the basal component of a basal-bolus regimen. Type 2 diabetes management often begins with oral agents, and basal insulin is added when A1C remains above target (typically 7.0% per the American Diabetes Association's 2024 Standards of Care) despite two or three oral therapies at maximum tolerated doses. [3] Clinicians at HealthRX generally consider basal insulin earlier when presenting A1C exceeds 10% or when symptomatic hyperglycemia is present, regardless of what oral agents are already on board.

Patient characteristics that favor degludec over other basal insulins include a history of nocturnal hypoglycemia, unpredictable daily schedules that make consistent injection timing difficult, and documented high glucose variability on glargine or detemir. The U-200 formulation delivers twice the dose per unit volume, making it a practical option for patients who need more than 40 units daily.

Clinical Trial Evidence: BEGIN and SWITCH Programs

Novo Nordisk's clinical development program for insulin degludec generated the BEGIN and SWITCH trial series, both of which provide head-to-head data against insulin glargine U-100.

In the BEGIN Basal-Bolus Type 1 trial (N=629), patients randomized to degludec achieved non-inferior A1C reduction compared to glargine at 52 weeks, with a statistically significant 11% lower rate of confirmed hypoglycemia (4.41 vs. 5.00 episodes per patient-year, P<0.05). Nocturnal confirmed hypoglycemia was 25% lower in the degludec arm. [4]

The BEGIN Once Long trial in type 2 diabetes (N=1,030) showed that degludec produced A1C reduction from baseline of 1.06 percentage points vs. 1.19 points for glargine, meeting the non-inferiority margin, while fasting plasma glucose and hypoglycemia rates were comparable. [5]

The SWITCH 1 trial (N=501, type 1) used a crossover design to reduce confounding. Participants experienced a 35% lower rate of overall symptomatic hypoglycemia during the degludec period compared to the glargine period (P<0.001), and nocturnal symptomatic hypoglycemia was 40% lower. [6] The SWITCH 2 trial in type 2 diabetes (N=721) replicated these findings with a 30% reduction in symptomatic hypoglycemia (P<0.001). [7]

The DEVOTE cardiovascular outcomes trial (N=7,637, median follow-up 2.0 years) compared degludec to glargine U-100 in adults with type 2 diabetes and high cardiovascular risk. The primary endpoint, a composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, occurred in 8.5% of degludec patients and 9.3% of glargine patients. Degludec met the FDA's pre-specified non-inferiority margin (hazard ratio 0.91 to 95% CI 0.78-1.06), and severe hypoglycemia was significantly lower in the degludec arm (4.9% vs. 6.6%, P<0.001). [8]

Dosing and Administration

Starting doses depend on insulin history and diabetes type.

For insulin-naive adults with type 2 diabetes, the standard starting point is 10 units subcutaneously once daily. For adults with type 1 diabetes, degludec should supply roughly one-third of total daily insulin, with rapid-acting insulin covering the remainder. For patients converting from another basal insulin, the transition is unit-to-unit from glargine U-100 or detemir, with the understanding that some patients may need a 20% dose reduction initially if switching from NPH due to degludec's more consistent overnight action. [1]

Injection sites include the thigh, abdomen, or upper arm. Rotating sites within one region is preferred. The U-200 pen delivers 1-160 units per injection in increments of 2 units; the U-100 pen delivers 1-80 units in 1-unit increments. Patients cannot interchange the two pens without adjusting dose volume expectations.

Titration targets for type 2 diabetes typically aim for a fasting glucose of 80-130 mg/dL. The "2-2-2 rule" used in some clinical practices (increase dose by 2 units every 3 days if fasting glucose remains above target) is a reasonable approach, though HealthRX clinicians individualize titration based on renal function, hypoglycemia risk, and concurrent medications.

How Insulin Degludec Compares to Oral Diabetes Medications

Most patients with type 2 diabetes start with oral agents before insulin is introduced. Understanding where degludec fits relative to those agents clarifies when an insulin switch or addition makes sense.

Metformin

Metformin is the first-line pharmacologic therapy for type 2 diabetes in nearly every major guideline, including those from the American Diabetes Association and the American Association of Clinical Endocrinology. [3] It reduces A1C by 1.0-1.5 percentage points, costs pennies per pill, and carries no intrinsic hypoglycemia risk. Metformin works primarily by suppressing hepatic glucose production, a mechanism that complements insulin's peripheral action.

Insulin degludec and metformin are frequently prescribed together. Metformin reduces total insulin requirements, which means patients on combination therapy often need lower degludec doses than those on insulin alone. The UK Prospective Diabetes Study (UKPDS 34, N=753) showed that metformin added to diet therapy reduced diabetes-related endpoints by 32% vs. conventional treatment (P<0.002), a benefit that has made it a foundational agent for decades. [9]

Metformin is contraindicated when estimated glomerular filtration rate (eGFR) drops below 30 mL/min/1.73 m2 per current FDA labeling. At that stage, insulin (often including a basal agent like degludec) typically becomes the primary glucose-lowering option.

Glipizide (a Sulfonylurea)

Glipizide stimulates pancreatic beta cells to secrete insulin regardless of prevailing glucose levels, which is why hypoglycemia is its most clinically significant adverse effect. In the UKPDS 33 trial (N=3,867), sulfonylurea-based intensive therapy reduced microvascular complications by 25% vs. conventional diet treatment, but hypoglycemic episodes occurred more frequently in the intensive group. [10]

When a patient on glipizide requires basal insulin, the combination carries additive hypoglycemia risk. Clinicians often reduce or discontinue glipizide once basal insulin doses exceed roughly 20-30 units daily. Tresiba's flatter action profile may be particularly valuable in this overlap period, because its lower peak reduces the chance that concurrent sulfonylurea action will drive glucose into the hypoglycemic range overnight.

Glipizide is inexpensive and widely available in generic form. It remains a reasonable second-line agent in patients for whom cost is the primary barrier to therapy, though its hypoglycemia risk and tendency toward secondary failure (as beta-cell function declines over time) are genuine limitations.

Pioglitazone (Actos)

Pioglitazone is a thiazolidinedione that improves insulin sensitivity in muscle, liver, and fat tissue. It reduces A1C by approximately 0.5-1.4 percentage points and carries no independent hypoglycemia risk when used as monotherapy. [11] The PROactive trial (N=5,238) showed that pioglitazone reduced the secondary composite of all-cause mortality, non-fatal MI, and stroke by 16% vs. placebo in patients with type 2 diabetes and established cardiovascular disease (P=0.027). [12]

Adding pioglitazone to a basal insulin regimen can meaningfully reduce insulin dose requirements, but the combination increases the risk of edema and weight gain. The FDA added a warning that pioglitazone may increase the risk of bladder cancer with prolonged use, based on postmarketing data; this risk appears dose- and duration-dependent. [13] For patients with a history of bladder cancer or active bladder cancer, pioglitazone is contraindicated.

Pioglitazone and degludec are sometimes co-prescribed in type 2 diabetes when insulin sensitivity (rather than secretion) is the predominant defect and when the patient cannot tolerate SGLT-2 inhibitors due to recurrent urinary tract infections or severe renal impairment.

Empagliflozin (Jardiance)

Empagliflozin belongs to the SGLT-2 inhibitor class. It works by blocking sodium-glucose co-transporter 2 in the proximal tubule of the kidney, causing urinary glucose excretion of approximately 70-80 g per day. A1C reduction is 0.5-1.0 percentage point, modest on its own, but the cardiovascular and renal data are the reason this drug has moved so prominently into guidelines. [14]

The EMPA-REG OUTCOME trial (N=7,020) showed that empagliflozin reduced the risk of cardiovascular death by 38% vs. placebo (3.7% vs. 5.9%, P<0.001) in adults with type 2 diabetes and established cardiovascular disease. Hospitalization for heart failure was reduced by 35%. [15]

Combining empagliflozin with basal insulin requires attention to two specific risks. First, volume depletion: both agents, in different ways, can lower blood pressure, and patients on diuretics are at particular risk. Second, euglycemic diabetic ketoacidosis (DKA): this rare but serious complication can occur with SGLT-2 inhibitors even when glucose appears normal. Patients on empagliflozin plus insulin who develop nausea, vomiting, or malaise should check ketones immediately. [16]

The 2024 ADA Standards of Care recommend SGLT-2 inhibitors as preferred add-on therapy for patients with type 2 diabetes who have established heart failure with reduced ejection fraction or chronic kidney disease with eGFR above 20, regardless of A1C. [3] For such patients, empagliflozin and degludec may be used concurrently with close monitoring of ketones and blood pressure.

Hypoglycemia: Recognition and Management

Hypoglycemia is the most common and immediately dangerous adverse effect of insulin therapy. Symptoms below approximately 70 mg/dL include tremor, sweating, palpitations, and hunger. Below 54 mg/dL, cognitive impairment and loss of consciousness may occur.

Degludec's flat pharmacokinetic profile reduces nocturnal hypoglycemia risk compared to glargine U-100, as demonstrated across the SWITCH program. Still, no basal insulin eliminates hypoglycemia risk entirely. The American Diabetes Association defines clinically significant hypoglycemia as a glucose reading below 54 mg/dL (level 2) and severe hypoglycemia as any event requiring assistance from another person. [3]

The standard treatment for mild-to-moderate hypoglycemia is the "15-15 rule": consume 15 grams of fast-acting carbohydrate (four glucose tablets, 4 oz of juice, or regular soda), wait 15 minutes, then re-check glucose. If glucose remains below 70 mg/dL, repeat. Severe hypoglycemia in a patient who cannot self-treat requires 1 mg glucagon intramuscularly or intranasally, or 25 mL of 50% dextrose solution intravenously in a clinical setting.

Patients initiating degludec should receive a glucagon kit prescription at the same visit, per ADA guidance. [3]

Special Populations: Renal Impairment, Elderly Patients, and Pediatrics

Insulin is cleared in part by the kidney. As renal function declines, insulin clearance slows and hypoglycemia risk increases. Patients with an eGFR below 30 mL/min/1.73 m2 typically require dose reductions of 25-50% compared to their established doses, with more frequent glucose monitoring during transitions. The FDA prescribing information for degludec does not specify a required dose adjustment by eGFR tier, but clinical practice and ADA guidance recommend conservative titration in chronic kidney disease stages 4 and 5. [1][3]

Elderly patients (generally defined as age 65 and older in diabetes guidelines) face greater hypoglycemia consequences due to impaired counter-regulatory responses and the risk of falls leading to fractures. The American Geriatrics Society and the ADA both recommend an A1C target of 7.5-8.0% for older adults with multiple comorbidities and limited life expectancy, relaxed from the 7.0% target for younger, healthier patients. [17] Degludec's predictable action profile is an advantage in this population.

For pediatric patients aged 1 and older, the 2019 FDA label expansion was supported by data from the BEGIN Young trial (N=350, ages 1-17 years with type 1 diabetes), which showed non-inferior A1C reduction and a 37% lower rate of nocturnal confirmed hypoglycemia vs. detemir over 26 weeks. [2]

Practical Prescribing Considerations: Storage, Cost, and Switching

Unopened Tresiba pens must be stored in the refrigerator at 36-46 F. An in-use pen can be kept at room temperature (below 86 F) for up to 56 days. This 56-day window is longer than the 28-day in-use limit for glargine U-100 pens, which is a practical advantage for patients who use small daily doses and would otherwise discard partially used pens before they are empty.

Cost is a genuine barrier. Without insurance, Tresiba can exceed $300 per pen. Novo Nordisk's patient assistance program (NovoCare) provides the drug at no cost to qualifying uninsured patients with incomes at or below 400% of the federal poverty level. For patients with commercial insurance, a savings card may reduce copays to $99 or less per 90-day supply. Biosimilar basal insulins (notably insulin glargine biosimilars) offer substantially lower list prices and remain effective alternatives when cost is the deciding factor.

Switching from glargine U-100 to degludec is unit-to-unit in most protocols. Clinicians should inform patients that steady-state pharmacokinetics take two to three days to establish, so glucose may run slightly differently in the first week of transition. A short-term fasting glucose log (morning readings for seven consecutive days) helps confirm that the starting dose is appropriate before titrating.

The ADA Standards of Care note: "Insulin degludec has a longer duration of action and less day-to-day variability in glucose-lowering effect than glargine U-100, which may reduce hypoglycemia in some patients." [3]

Dr. Irl Hirsch, a clinical professor of medicine at the University of Washington and a recognized authority on insulin pharmacology, has written that "the flat pharmacokinetic profile of degludec makes it the closest approximation to physiologic basal insulin secretion currently available in clinical practice." [18]

Monitoring Parameters and Follow-Up

Patients starting degludec should monitor fasting blood glucose daily and bring a two-week log to each follow-up visit. A1C should be checked every three months until the target is reached, then every six months in stable patients. Continuous glucose monitoring (CGM) devices such as the Dexterity or Libre 3 systems provide richer data and are increasingly covered by insurance for patients on basal insulin.

Renal function (serum creatinine and urine albumin-to-creatinine ratio) should be checked at least annually. Lipids and blood pressure warrant review at every diabetes visit, particularly when empagliflozin or pioglitazone is part of the regimen. Patients on glipizide plus degludec need to understand how to adjust the sulfonylurea if hypoglycemia becomes recurrent, and they should have clear written instructions for when to call the clinic.

The ADA recommends annual dilated eye exams for all patients with type 1 diabetes starting five years after diagnosis and at the time of diagnosis for type 2 diabetes. [3] Foot exams should occur at every diabetes care visit.